ALCJ Stock Overview
Crossject Société Anonyme develops needle-free injection systems in France.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Crossject Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.15 |
| 52 Week High | €5.96 |
| 52 Week Low | €1.83 |
| Beta | 0.84 |
| 1 Month Change | -37.13% |
| 3 Month Change | -59.81% |
| 1 Year Change | -42.74% |
| 3 Year Change | -32.60% |
| 5 Year Change | 3.37% |
| Change since IPO | -77.42% |
Recent News & Updates
Shareholder Returns
| ALCJ | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 10.3% | -0.8% | -0.1% |
| 1Y | -42.7% | 9.1% | 1.3% |
Return vs Industry: ALCJ underperformed the French Medical Equipment industry which returned 9.1% over the past year.
Return vs Market: ALCJ underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| ALCJ volatility | |
|---|---|
| ALCJ Average Weekly Movement | 15.1% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALCJ's share price has been volatile over the past 3 months.
Volatility Over Time: ALCJ's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 110 | Patrick Alexandre | www.crossject.com |
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.
Crossject Société Anonyme Fundamentals Summary
| ALCJ fundamental statistics | |
|---|---|
| Market cap | €81.76m |
| Earnings (TTM) | -€8.47m |
| Revenue (TTM) | €12.83m |
6.4x
P/S Ratio-9.7x
P/E RatioIs ALCJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCJ income statement (TTM) | |
|---|---|
| Revenue | €12.83m |
| Cost of Revenue | €10.46m |
| Gross Profit | €2.36m |
| Other Expenses | €10.83m |
| Earnings | -€8.47m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 18.42% |
| Net Profit Margin | -66.01% |
| Debt/Equity Ratio | -1,695.9% |
How did ALCJ perform over the long term?
See historical performance and comparison